Company Overview
Company Type: Public Company
Website: defencetherapeutics.com
Number of Employees: -
Ticker: DTC (CNSX)
Year Founded: 2017


Business Description
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
106.3
Total Enterprise Value
105.1
EBIT
(6.9)
Cash & ST Invst.
2.9
P/Diluted EPS Before Extra
NM
Net Income
(7.2)
Total Debt
1.6
Price/Tang BV
78.6x
Capital Expenditure
(0.1)
Total Assets
3.1




Currency in CAD in mm, LTM as of Mar-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Plouffe, Sebastien 
CEO, President & Director
Meagher, Patrick Joseph
CFO & Director
Rafei, Moutih 
Chief Scientific Officer & Director
Beaudoin, Simon 
Chief Technical Science Officer
Cesarone, Carrie 
Corporate Secretary

Key Board Members
Name
Title
Plouffe, Sebastien 
CEO, President & Director
Meagher, Patrick Joseph
CFO & Director
Rafei, Moutih 
Chief Scientific Officer & Director
Lobenberg, Raimar 
Independent Director
Grauer, Kwin 
Director
Meterissian, Sarkis 
Independent Director
Shammaa, Riam 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
1680 – 200 Burrard Street | Vancouver, BC | V6C 3L6 | Canada

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 2.42
Market Cap (mm)
106.3
Open
 2.42
Shares Out. (mm)
43.9
Previous Close
 2.42
Float %
95.2%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 2.50/ 2.42
Diluted EPS Excl. Extra Items
(0.19)
52 wk High/Low
 4.85/ 1.45
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0023
Avg 3M Dly Vlm (mm)
0.01
Beta 5Y
2.20


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:DTC - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-28-2022
Nov-16-2022
Private Placement
Target
Defence Therapeutics Inc. (CNSX:DTC)


1.77
Jul-28-2017
Cancelled
Merger/Acquisition
Buyer
Woden Venture Capital Corporation
Accum Therapeutics Inc. (nka:Defence Therapeutics Inc. (CNSX:DTC))

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-25-2023
Product-Related Announcements
Defence Therapeutics Inc. Announces Accum-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines
Jul-18-2023
Strategic Alliances
Defence Therapeutics Inc. Successfully Completes the First Milestone of Its Collaboration Agreement with Orano
Jul-04-2023
Strategic Alliances
Defence Therapeutics Inc. and Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology
Jun-20-2023
Product-Related Announcements
Defence Therapeutics Inc. Announces the Publication of Its New International (PCT) Patent Application Demonstrating the Effectiveness of Defence's AccumTM-Based Technology
Jun-16-2023
Product-Related Announcements
Defence Therapeutics Inc. Announces Reach the Final Stages of Its AccuTOX^TM Chemistry, Manufacturing and Controls


Advisors
Most Recent Auditor
Crowe MacKay LLP


Most Recent Auditor
Crowe mackay LLP


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Plouffe, Sebastien 

1,600,000

3.64

4.0

Nov-03-2022


Meagher C.A., C.P.A., CA, CPA, Patrick Joseph

350,000

0.80

0.9

Nov-03-2022


Lobenberg, Raimar 

100,000

0.23

0.3

Nov-03-2022


Rafei Ph.D., Moutih 

70,000

0.16

0.2

Nov-03-2022


Grauer C.A., CPA, Kwin 

10,000

0.02

0.0

Jul-24-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Grauer C.A., CPA, Kwin 
10,000
2,500

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Accum, AccuTOX (Future), AccuVAC-PT001 (Future), AccuVAC-PT007 (Future)


Upcoming Events
Date/Time
Type
Oct-24-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-25-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
42 KB
Sep-25-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
42 KB
Sep-22-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
35 KB
Sep-12-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
48 KB
Sep-05-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
37 KB
Jul-18-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
39 KB
Jul-05-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
37 KB
Jul-04-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
36 KB
Jun-28-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
85 KB
Jun-20-2023
Defence Therapeutics Inc. (CNSX:DTC)
SEDAR
News Releases
44 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Grauer C.A., CPA, Kwin  (Director)
Jul-24-2023
Class A Common Shares
2,500
7,296
Open Market Acquisition
33.33
Multiple
Grauer C.A., CPA, Kwin  (Director)
May-08-2023
Class A Common Shares
2,500
7,457
Open Market Acquisition
50.00
Multiple
Grauer C.A., CPA, Kwin  (Director)
Mar-30-2023
Class A Common Shares
2,800
9,949
Open Market Acquisition
127.27
Multiple
Grauer C.A., CPA, Kwin  (Director)
Mar-20-2023
Class A Common Shares
2,200
7,733
Open Market Acquisition
New
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Plouffe, Sebastien 
CEO, President & Director
-
-
Splouffe@defencetherapeutics.com
Meagher, Patrick Joseph
CFO & Director
-
-

Rafei, Moutih 
Chief Scientific Officer & Director
-
-

Lobenberg, Raimar 
Independent Director
-
-

Grauer, Kwin 
Director
-
-

Meterissian, Sarkis 
Independent Director
-
-

Shammaa, Riam 
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Plouffe, Sebastien 
CEO, President & Director
-
-
Splouffe@defencetherapeutics.com
Meagher, Patrick Joseph
CFO & Director
-
-

Rafei, Moutih 
Chief Scientific Officer & Director
-
-

Beaudoin, Simon 
Chief Technical Science Officer
-
-

Cesarone, Carrie 
Corporate Secretary
-
-
carrie@rsdcapital.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
